Latest news with #235
The Sun
3 days ago
- Business
- The Sun
Reskilling polytechnic lecturers boosts Malaysia's TVET sector
JASIN: Efforts to enhance Malaysia's Technical and Vocational Education and Training (TVET) sector include reskilling and upskilling programmes for Polytechnics and Community Colleges (PolyCC) lecturers. Polytechnic and Community College Education Department director-general Datuk Dr Mohd Zahari Ismail highlighted industrial sabbaticals as a key initiative. 'This measure proves the PolyCC's conviction to ensure that teaching methods remain relevant and in line with industry needs,' he said. He noted that these programmes help lecturers gain real industry experience, improving teaching quality and employer confidence in graduates. Mohd Zahari spoke at the 23rd Convocation of Merlimau Melaka Polytechnic (PMM), where PMM received RM188,235 in Trans-Tech 4TVET funding. The institution also earned the High-Performing PolyCC Award and a Certificate of Appreciation for industrial training improvements. PMM director Norizam Sekak reported an 86.4% graduate employment rate within six months of graduation. Of these, 63.1% secured jobs in their field of study, while 11.3% became entrepreneurs. Another 13.6% chose to pursue further studies, reflecting the institution's strong graduate outcomes. Norizam credited the MeritKITA system and TVET on Campus (ToC) programme for enhancing student employability. PMM also won the Lifelong Learning Award at the 2025 MQA Awards and secured RM380,560 in research grants. The institution is developing a Green Campus with solar roofs and a Digital Entrepreneurship Centre in partnership with MDEC. Plans for an Artificial Intelligence Digital Centre (AIDEx) aim to accelerate PMM's digital campus transformation. A total of 1,398 graduates received diplomas during the two-day convocation at Merlimau Polytechnic Platinum Hall. - Bernama
TimesLIVE
24-06-2025
- Automotive
- TimesLIVE
Nissan turnaround plan under spotlight at shareholder meeting
Nissan Motor will face scrutiny over its deepening crisis at an annual general meeting on Tuesday, where investors will also vote on an activist proposal urging it to take action on listed subsidiary Nissan Shatai. It is anyone's guess whether new boss Ivan Espinosa will be able to halt the sharp decline at the carmaker, where shares have fallen 36% over the past year and dividend payments have been suspended. Nissan reported a $4.5bn (R80,235,495,000) net loss in the last financial year and there is no guarantee it will return to profit this year. So far it has declined to give a full-year earnings forecast. Espinosa has laid out plans for big cuts, including closing seven plants and shedding a total of 20,000 jobs, or around 15% of Nissan's workforce. One Tokyo-based activist investor, Strategic Capital, thinks the overhaul should include Nissan taking action on its listed subsidiary. Japanese companies are under increasing pressure from the Tokyo Stock Exchange and regulators to clear up "parent-child listings", which are seen as unfair to minority shareholders and a drag on governance. In one prominent example, Toyota Motor this month unveiled plans to take private its listed subsidiary, Toyota Industries, in a complex, $33bn (R588,305,764,200) transaction that some shareholders have said undervalues the forklift operator. Toyota likely took action because "it felt pressure from shareholders and thought it had to change", Tsuyoshi Maruki, CEO of Strategic Capital, said in an interview with Reuters on Monday. He said he hoped Nissan's management could also give the issue similar consideration. Nissan owns 50% of Nissan Shatai, which manufactures cars for the carmaker. Strategic Capital owns 3.5% of Nissan Shatai. It has also acquired a small stake in Nissan, allowing it to submit proposals to the general meeting. It has proposed Nissan change its articles of incorporation so it would be required to annually examine its relationship with listed subsidiaries and disclose what action, if any, it planned to take.
Yahoo
07-06-2025
- Business
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
TimesLIVE
06-06-2025
- Business
- TimesLIVE
GNU ministers spent R200m of taxpayers' money on travelling since taking office
Ministers in the government of national unity (GNU) have spent more than R200m on travel expenses since July last year. This was revealed by ActionSA through its GNU performance tracker after receiving replies to parliamentary questions sent to ministers. This week, the party said Deputy President Paul Mashatile and his staff splurged more than R2m on travel expenses for transport and accommodation since last year. In a written reply, Mashatile said he has been on four international trips - to Ireland, Botswana, Zimbabwe and, recently, Japan. A total of R613,214 was spent on flights, R1,235,569 on accommodation and R410,926 for ground transport for all trips. Other costs included laundry services at R8,033 and R51,393 for restaurant services. ActionSA MP Alan Beesley criticised the spending, calling it 'executive indulgence' and 'wasteful expenditure'. 'This sort of wasteful expenditure, an extension of ANC excess now rebranded under the GNU, has become business as usual for the world's most bloated executive,' Beesley said. 'South Africans deserve leadership that puts people before perks and not a R200m travel spree by the world's largest cabinet.' The sport, arts and culture department's travel expenses have also raised concern. Minister Gayton McKenzie said he and his staff undertook 11 international trips costing more than R2m. R164,556 was paid for a trip to Burkina Faso that never took place. 'Not only is this spending exorbitant, but it is riddled with red flags, gaps and inconsistencies. The public paid for flights and accommodation for an event that was abandoned, a textbook case of wasteful expenditure, as defined by the Public Finance Management Act. 'Unless the minister can demonstrate that this loss was unavoidable and efforts were made to recover the funds, this reflects a serious failure of financial oversight and internal control.' ActionSA has introduced the Enhanced Cut Cabinet Perks Bill to address unchecked government spending. 'This bill seeks to slash ministerial perks and restore much-needed fiscal discipline.'
Yahoo
06-06-2025
- Business
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
